Proteoglycans.

Collagen provides the tensile fibre network of skin and cartilage, and proteoglycans fill the space between fibrils and hold the water that gives the tissue its compressive resistance. Small leucine-rich proteoglycans such as decorin bind directly to collagen fibrils and regulate how thick those fibrils grow. Supplying substrate and signal for both halves of the matrix is the logic behind combined formulas. Whether oral co-supplementation changes matrix composition in humans is not settled.

In cartilage, hundreds of aggrecan molecules attach along a single hyaluronan chain to build the proteoglycan aggregate. Hyaluronan is the backbone and the proteoglycan is the bottlebrush hung off it. The two are not alternatives but components of one assembly, which is why they appear together in joint and skin formulas. Oral intake of either is broken down before absorption, so any benefit runs through fragments and signalling rather than direct incorporation.

Chondroitin sulfate chains are the glycosaminoglycans covalently attached to the aggrecan core protein. A proteoglycan preparation is in large part a chondroitin sulfate delivery vehicle with the protein core still attached. Taking both is closer to overlapping than to combining. Formulators should regard the label total rather than the number of ingredients.

Collagen cannot form a stable triple helix without hydroxylation of proline and lysine residues, and the enzymes that do that work require ascorbate to keep their iron centre reduced. Proteoglycans are secreted into a matrix whose scaffold is that collagen. Without adequate vitamin C the scaffold is defective regardless of how much matrix substrate is supplied. This is one of the cleanest cofactor relationships in connective tissue biology.

Glycosaminoglycan chains are built from repeating amino sugar and uronic acid units, and glucosamine sits upstream as a substrate for that assembly. Supplying the monomer and the assembled polymer is a substrate-plus-product pairing. Cell studies show glucosamine can increase glycosaminoglycan output, though the flux limitation in a well-fed human is unclear. Read it as mechanistic rather than clinical.

The transferases that add successive sugars to a growing glycosaminoglycan chain require divalent manganese in the active site. Manganese deficiency produces visibly abnormal cartilage in animal models through this route. Ordinary diets supply enough, so this is a requirement rather than a reason to add more. It explains why manganese appears in older joint formulas.

An intact proteoglycan is a large glycosylated protein and is not absorbed as such. Gut proteases and glycosidases cleave it into peptides and oligosaccharides before anything crosses the epithelium. Any oral proteoglycan therefore acts through its fragments, not through the intact molecule reaching the tissue. Marketing that implies direct incorporation into cartilage is not supported by absorption physiology.

Aggrecanases and matrix metalloproteinases, the enzymes that degrade proteoglycans in tissue, are zinc-dependent. Zinc is also required for the transcription factors that govern matrix synthesis. The metal sits on both sides of matrix turnover, so more is not straightforwardly better. Adequacy is the relevant goal.

Lysyl oxidase cross-links collagen and elastin, and it cannot work without copper at its active site. The proteoglycan-rich matrix depends on that cross-linked fibre network for its mechanical properties. Copper deficiency produces fragile connective tissue for this reason. High zinc intake lowers copper absorption, so joint formulas heavy in zinc should account for it.

Chondroitin and keratan sulfate chains carry sulfate groups added from PAPS, which is built from sulfate derived ultimately from sulfur amino acids. MSM is a sulfur donor in principle. Whether it meaningfully raises the sulfate pool in a person eating adequate protein has not been demonstrated. The pairing is common in formulas and thin in evidence.

Chondrocytes carry vitamin D receptors, and calcitriol influences their differentiation and matrix gene expression. The vitamin also governs calcium handling at the cartilage-bone interface. This is a regulatory input to matrix biology rather than a substrate contribution. It is relevant background for joint formulas rather than a direct pairing.

Silicon is concentrated in connective tissue and silicon-deficient animals develop abnormal cartilage and bone matrix. Proposed roles include a part in glycosaminoglycan cross-linking. Human evidence is sparse and mostly observational for bone density rather than cartilage. Read this as suggestive.